Lapatinib for breast cancer: a review of the current literature

Author： MacFarlane Robyn J   Gelmon Karen A  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.10, Iss.1, 2011-01, pp. : 109-121

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lapatinib: A Review of its Use in the Treatment of HER2-Overexpressing, Trastuzumab-Refractory, Advanced or Metastatic Breast Cancer

By Frampton James E.  

Drugs, Vol. 69, Iss. 15, 2009-10 ,pp. : 2125-2148

Adis International

Access to resources Recommend Favorite

Lapatinib no help in HER-2-negative breast cancer

By  

Inpharma, Vol. 1, Iss. 1663, 2008-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Lapatinib may be active in urogenital, breast cancer

By  

Inpharma, Vol. 1, Iss. 1493, 2005-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Novel Approaches to Advanced Breast Cancer: Bevacizumab and Lapatinib

By Mayer Erica L.   Lin Nancy U.   Burstein Harold J.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 5, Iss. 3, 2007-03 ,pp. : 314-323

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients

By  

Clinical Pharmacology In Drug Development, Vol. 2, Iss. 4, 2013-10 ,pp. : 336-341

John Wiley & Sons Inc

Access to resources Recommend Favorite